CyanVac LLC, a biotechnology company, received federal funding to conduct a comparative Phase 2b study of CVXGA, its PIV5-based intranasal vaccine candidate for COVID-19. This funding is part of the Project NextGen initiative, aimed at developing innovative vaccines for COVID-19.
Through BARDA‘s Clinical Studies Network, the study will compare CVXGA to an FDA-approved mRNA-based COVID-19 vaccine in a 10,000-participant randomized double-blinded trial. It will assess efficacy, safety, and immunogenicity, including preventing asymptomatic infections.
The PIV5 vector has been shown to replicate safely in clinical trials, stimulating cellular, mucosal, and humoral immunity with minimal side effects. An intranasal vaccine using this vector could potentially reduce disease transmission.
CyanVac will sponsor the study, which is expected to begin in fall 2024. The company believes the successful development of CVXGA will demonstrate the capabilities of its PIV5 platform and pave the way for PIV5-based vaccines for other emerging infectious diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
